The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.
Julien Taïeb
Honoraria - Merck Serono; Sanofi
Jean-François Emile
No relevant relationships to disclose
Karine Le Malicot
No relevant relationships to disclose
Aziz Zaanan
No relevant relationships to disclose
Josep Tabernero
Consultant or Advisory Role - Merck Serono; Sanofi
Honoraria - Merck Serono; Sanofi
Enrico Mini
No relevant relationships to disclose
Philippe Rougier
Consultant or Advisory Role - Merck Serono; Sanofi
Jean Luc VAN Laethem
No relevant relationships to disclose
John A. Bridgewater
Consultant or Advisory Role - Merck Serono; Sanofi
Gunnar Folprecht
Honoraria - Merck Serono
Ramon Salazar
Honoraria - Merck Serono
Ayman Zawadi
No relevant relationships to disclose
Eric Van Cutsem
No relevant relationships to disclose
Come Lepage
No relevant relationships to disclose
Pierre Laurent-Puig
Honoraria - Merck Serono
Helene Blons
No relevant relationships to disclose